<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395222</url>
  </required_header>
  <id_info>
    <org_study_id>19-08020738</org_study_id>
    <nct_id>NCT04395222</nct_id>
  </id_info>
  <brief_title>Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation</brief_title>
  <official_title>A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of reducing and ultimately eliminating&#xD;
      anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and&#xD;
      replacing it with tocilizumab, an IL-6 receptor monoclonal antibody, to improve immune&#xD;
      reconstitution and reduce relapse while preserving low rates of graft failure and graft&#xD;
      versus host disease (GVHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective phase II non-inferiority study investigating tocilizumab as a&#xD;
      potential alternative to anti-thymocyte globulin (ATG) in haplo-cord transplantation. It is a&#xD;
      single-center study based at Weill Cornell Medicine/NewYork Presbyterian Hospital.&#xD;
&#xD;
      The hypothesis is that tocilizumab is a safe and effective alternative to ATG in haplo-cord&#xD;
      transplantation, facilitating transient engraftment of the haplo-identical stem cell graft&#xD;
      without prolonged neutropenia or second nadir prior to durable cord engraftment while also&#xD;
      preventing graft versus host disease (GVHD).&#xD;
&#xD;
      This study plans to enroll patients with hematologic malignancies in need of alternate donor&#xD;
      transplant. All subjects will be conditioned with fludarabine, melphalan and total body&#xD;
      irradiation (TBI), followed by a single dose of tocilizumab 8 mg/kg on Day -1. Patients will&#xD;
      be enrolled into 4 successive cohorts, initially administering the current standard 3 doses&#xD;
      of ATG 1.5 mg/kg (total 4.5 mg/kg). In the absence of safety signals, we will drop one dose&#xD;
      of ATG in successive cohorts until the drug ultimately has been eliminated.&#xD;
&#xD;
      The primary endpoint of the study is successful haplo-derived neutrophil engraftment.&#xD;
      Treatment will only be of interest if there is evidence that this rate is greater than 60%.&#xD;
      If there are 4 or fewer successes, that dose group will be deemed unacceptable and the next&#xD;
      higher ATG dose for which there were 5 or more success will be expanded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with successful haplo-derived neutrophil engraftment</measure>
    <time_frame>21 days post-transplant</time_frame>
    <description>This is defined as:&#xD;
Achieve an absolute neutrophil count (ANC) of 500 cells/microL for three consecutive days with the first on or prior to Day +21 post-transplant, AND&#xD;
Absence of a second nadir - a drop in the ANC to &lt;300 cells/microL for five consecutive days - after initial neutrophil recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Time elapsed between Day 0 and progression of the underlying malignancy for which the transplant was performed, assessed up to 5 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Time elapsed between Day 0 and death from any cause, assessed up to 5 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-Related Mortality</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Proportion of deaths which cannot be explained by persistence, relapse or progression of the underlying malignancy once the preparative regimen starts, assessed up to 5 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Platelet Engraftment Success</measure>
    <time_frame>6 months post-transplant</time_frame>
    <description>Proportion of patients who successfully achieve platelet engraftment, defined as a platelet count of &gt;20k/microL for three consecutive days without transfusion support for seven consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Failure of the Haplo-Graft</measure>
    <time_frame>21 days post-transplant</time_frame>
    <description>Proportion of patients with a failed haplo-graft, defined as the absence of neutrophil engraftment by Day +21 or a drop in the absolute neutrophil count to &lt;0.3 cells/microL for five consecutive days occurring after initial neutrophil engraftment within the first 3 weeks post-transplantation (second nadir)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Acute Graft-versus-Host Disease</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Proportion of patients who develop acute graft-versus-host disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Chronic Graft-versus-Host Disease</measure>
    <time_frame>5 years post-transplant</time_frame>
    <description>Proportion of patients who develop chronic graft-versus-host disease</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Bone Marrow Transplant</condition>
  <arm_group>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen.&#xD;
Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)&#xD;
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.&#xD;
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.&#xD;
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen.&#xD;
Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)&#xD;
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.&#xD;
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.&#xD;
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen.&#xD;
Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)&#xD;
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.&#xD;
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.&#xD;
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATG Group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old)&#xD;
Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen.&#xD;
Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen.&#xD;
Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin (rabbit)</intervention_name>
    <description>Anti-thymocyte globulin (ATG) 1.5 mg/kg</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen</description>
    <arm_group_label>ATG Group I</arm_group_label>
    <arm_group_label>ATG Group II</arm_group_label>
    <arm_group_label>ATG Group III</arm_group_label>
    <arm_group_label>ATG Group IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must have a confirmed diagnosis of one of the following:&#xD;
&#xD;
               1. Relapsed or refractory acute leukemia (myeloid or lymphoid)&#xD;
&#xD;
               2. Acute leukemia in first remission at high-risk for recurrence&#xD;
&#xD;
               3. Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis&#xD;
&#xD;
               4. Myelodysplastic syndromes&#xD;
&#xD;
               5. Chronic myeloproliferative disease&#xD;
&#xD;
               6. Recurrent, refractory or high-risk malignant lymphoma&#xD;
&#xD;
               7. Chronic lymphocytic leukemia, relapsed or with poor prognostic features&#xD;
&#xD;
               8. Multiple myeloma&#xD;
&#xD;
               9. Other hematological disorder in need of allogeneic transplant (e.g. blastoid&#xD;
                  dendritic cell neoplasm)&#xD;
&#xD;
          2. Age ≥ 18 years.&#xD;
&#xD;
          3. Likely to benefit from allogeneic transplant in the opinion of the transplant&#xD;
             physician.&#xD;
&#xD;
          4. An HLA-identical related or unrelated donor cannot be identified within an appropriate&#xD;
             time frame.&#xD;
&#xD;
          5. Karnofsky Performance Status (KPS) of ≥ 70%.&#xD;
&#xD;
          6. Acceptable organ function as defined below:&#xD;
&#xD;
               1. Serum bilirubin: &lt;2.0 mg/dL&#xD;
&#xD;
               2. ALT (SGPT) &lt;3x upper limit of normal (ULN)&#xD;
&#xD;
               3. Creatinine Clearance: &gt;50 mL/min/1.73m2 (eGFR as estimated by the modified MDRD&#xD;
                  equation)&#xD;
&#xD;
               4. Left ventricular ejection fraction &gt;40%&#xD;
&#xD;
               5. Pulmonary diffusion capacity &gt;40% predicted&#xD;
&#xD;
          7. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy is severely limited by concomitant illness or uncontrolled infection.&#xD;
&#xD;
          2. Evidence of chronic active hepatitis or cirrhosis&#xD;
&#xD;
          3. Uncontrolled HIV disease.&#xD;
&#xD;
          4. Pregnancy or lactation.&#xD;
&#xD;
          5. History of complicated diverticulitis, including fistulae, abscess formation or&#xD;
             gastrointestinal perforation&#xD;
&#xD;
          6. History of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition as tocilizumab, including known allergies to Chinese hamster&#xD;
             ovary cell products or other recombinant human or humanized antibodies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koen van Besien, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashlee You, RN</last_name>
    <phone>212-746-7117</phone>
    <email>ant9015@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>June Greenberg, RN</last_name>
    <phone>212-746-2651</phone>
    <email>jdg2002@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashlee You, RN</last_name>
      <phone>212-746-7117</phone>
      <email>ant9015@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Koen van Besien, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tocilizumab</keyword>
  <keyword>Haplo-Cord Transplant</keyword>
  <keyword>Allogeneic Transplant</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

